Samadzade U., Alızada S., Calıskan C., Mammadov O., Kara İ., Ozakbas S.
Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2025, Barcelona, İspanya, 24 - 26 Eylül 2025, ss.1718-1719, (Özet Bildiri)
-
Yayın Türü:
Bildiri / Özet Bildiri
-
Basıldığı Şehir:
Barcelona
-
Basıldığı Ülke:
İspanya
-
Sayfa Sayıları:
ss.1718-1719
-
Dokuz Eylül Üniversitesi Adresli:
Evet
Özet
Introduction: Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has been shown to effectively reduce disease activity and delay disability progression in both relapsing and progressive forms of multiple sclerosis (MS). This study aimed to evaluate the clinical trajectory of MS patients during the three years preceding and following the initiation of ocrelizumab therapy.
Objectives/Aims: This study aimed to evaluate the clinical trajectory of MS patients during the three years preceding and following the initiation of ocrelizumab therapy.
Methods: We conducted a retrospective analysis of 268 people with multiple sclerosis (pwMS) treated with ocrelizumab. Patients were stratified into relapsing-remitting MS (RRMS, n=138) and progressive MS (PMS; 111 secondary progressive MS, 19 primary progressive MS; total n=130) groups. Clinical outcomes were assessed by comparing annualized relapse rates (ARR) in the three years before and after treatment initiation. Expanded Disability Status Scale (EDSS) scores were recorded at three time points: three years before treatment, at the time of initiation, and three years post-initiation. In the post-treatment period, the proportion of patients achieving no evidence of disease activity (NEDA-3)—defined as the absence of clinical relapses, confirmed disability progression, and new or enlarging MRI lesions—was also evaluated.
Results: The mean age of the cohort was 53.2 years (SD = 12.1), with 63.4% female. The average age at MS onset was 30.8 years (SD = 10.2), and the mean disease duration was 22.3 years (SD = 8.8).
In the RRMS group, the ARR declined significantly from 0.35 (SD = 0.34) in the three years before treatment to 0.014 post-treatment (p < .001). EDSS scores remained stable (baseline: 3.57, SD = 1.76; year 3: 3.54, SD = 1.90; p = .765).
In the PMS group, the ARR decreased from 0.31 (SD = 0.35) to 0.0077 (SD = 0.05) after treatment (p < .001), with EDSS scores showing no significant change (baseline: 6.27, SD = 0.91; year 3: 6.36, SD = 0.91; p = .080).
Notably, NEDA-3 was achieved in 46.0% of RRMS patients and 54.6% of those with progressive MS over the three-year follow-up, highlighting the broad efficacy of ocrelizumab across different MS phenotypes.
Conclusion: This six-year observational window reveals that ocrelizumab substantially suppresses disease activity in both relapsing and progressive MS. The therapy was associated with a marked reduction in relapse rates and stabilization of disability over time. The achievement of NEDA-3 in a considerable proportion of patients, including those with progressive forms of MS, underscores the potential of ocrelizumab to effectively modify disease trajectory even in long-standing and advanced cases.